Control of extracellular matrix remodelling within ovarian tissues: Localization and regulation of gene expression of plasminogen activator inhibitor type-1 within the ovine corpus luteum

被引:0
|
作者
Smith, GW
Gentry, PC
Bao, B
Long, DK
Roberts, RM
Smith, MF
机构
[1] UNIV MISSOURI, DEPT ANIM SCI, COLUMBIA, MO 65211 USA
[2] UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA
来源
JOURNAL OF REPRODUCTION AND FERTILITY | 1997年 / 110卷 / 01期
关键词
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Extensive extracellular matrix remodelling occurs within the lifespan of the corpus luteum, particularly during corpus luteum formation and regression. A major mechanism for the regulation of extracellular matrix remodelling is via local production of specific proteinase inhibitors, such as the serine proteinase inhibitor plasminogen activator inhibitor type-1 (PAI-1). The objective of the present study was to characterize the localization, ontogeny and regulation of PAI-1 expression within ovine corpora lutea. Urokinase binding activity was detected within medium conditioned by ovine luteal cells. Production of PAI-1 by ovine luteal cells was confirmed by immunoprecipitating it from labelled proteins in culture medium. mRNA encoding PAI-1 was present within developing (day 3), mature (day 10) and regressing (30 h after prostaglandin F-2 alpha injection on day 10 after the onset of oestrus) corpora lutea as demonstrated by in situ hybridization. The ontogeny of PAI-1 mRNA expression was characterized within corpora lutea collected on days 3, 7, 10, 13 and 16 after the onset of oestrus (n = 4, 4, 4, 3 and 4, respectively). Expression of PAI-1 mRNA did not differ during the luteal phase (P = 0.06), although a trend for an increase in the amount of PAI-1 mRNA was observed on day 16. Expression of PAI-1 mRNA was also examined during luteal regression in corpora lutea collected 0, 6, 12, 24 and 36 h after injection of prostaglandin F-2 alpha on day 10 after the onset of oestrus (n = 4 at each time). Relative PAI-1 mRNA concentrations changed significantly during luteolysis induced by prostaglandin F-2 alpha (P = 0.0002). Administration of prostaglandin F-2 alpha resulted in a transient sevenfold increase in PAI-1 mRNA 6 h after injection (P = 0.0001) but by 12 h the amounts had returned to values similar to those detected on day 10. We conclude that PAI-1 is a major secretory product of ovine luteal cells and that a transient increase in PAI-1 mRNA occurs during luteolysis induced by prostaglandin F-2 alpha. PAI-1 probably plays a key local role in the control of extracellular proteolysis during the luteal phase.
引用
收藏
页码:107 / 114
页数:8
相关论文
共 50 条
  • [41] COORDINATED REGULATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 GENE-EXPRESSION IN HYPOPHYSECTOMIZED RAT OVARIES DURING GNRHA-INDUCED OVULATION
    LIU, YX
    LIU, K
    PENG, XR
    NY, T
    [J]. SCIENCE IN CHINA SERIES B-CHEMISTRY, 1994, 37 (07): : 820 - 830
  • [42] PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IS A POTENT NATURAL INHIBITOR OF EXTRACELLULAR-MATRIX DEGRADATION BY FIBROSARCOMA AND COLON-CARCINOMA CELLS
    CAJOT, JF
    BAMAT, J
    BERGONZELLI, GE
    KRUITHOF, EKO
    MEDCALF, RL
    TESTUZ, J
    SORDAT, B
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (18) : 6939 - 6943
  • [43] DEMONSTRATION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 (PAL-1) IN EXTRACELLULAR-MATRIX OF TYPE-II PNEUMOCYTES IN PRIMARY CULTURE
    PARTON, L
    WARBURTON, D
    LAUG, W
    [J]. CLINICAL RESEARCH, 1988, 36 (01): : A243 - A243
  • [44] DEFINITION OF EPITOPES WITHIN PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 (PAI-1) USING MULTIPLE PEPTIDE-SYNTHESIS
    PERRIE, AM
    MACGREGOR, IR
    BOOTH, NA
    [J]. FIBRINOLYSIS, 1993, 7 (04) : 257 - 263
  • [45] IMMUNOELECTRON MICROSCOPIC LOCALIZATION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN THE EXTRACELLULAR-MATRIX OF TRANSFORMING GROWTH FACTOR-BETA-ACTIVATED ENDOTHELIAL-CELLS
    PODOR, TJ
    LOSKUTOFF, DJ
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1992, 667 : 46 - 49
  • [46] Cell shape-dependent pathway of plasminogen activator inhibitor type-1 gene expression requires cytoskeletal reorganization
    Hawks, K
    Higgins, PJ
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1998, 176 (02) : 293 - 302
  • [47] Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells
    Sato, Masakazu
    Kawana, Kei
    Kiadachi, Katsuyu
    Fujimoto, Asaha
    Yoshida, Mitsuyo
    Nakamura, Hiroe
    Nishida, Haruka
    Inoue, Tomoko
    Taguchi, Ayumi
    Takahashi, Juri
    Kojima, Satoko
    Yamashita, Aki
    Tomio, Kensuke
    Nagamatsu, Takeshi
    Wada-Hiraike, Osamu
    Oda, Katsutoshi
    Osuga, Yutaka
    Fuji, Tomoyuki
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (02) : 829 - 835
  • [48] Posttranscriptional regulation of expression of plasminogen activator inhibitor type-1 by sphingosine 1-phosphate in HepG2 liver cells
    Iwaki, Soichiro
    Yamamura, Shuhei
    Asai, Moyoko
    Sobel, Burton E.
    Fujii, Satoshi
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2012, 1819 (11-12): : 1132 - 1141
  • [49] TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR AND TISSUE-TYPE PLASMINOGEN-ACTIVATOR GENE-EXPRESSION IN HTC RAT HEPATOMA-CELLS BY GLUCOCORTICOIDS AND CYCLIC-NUCLEOTIDES
    HEATON, JH
    KATHJU, S
    GELEHRTER, TD
    [J]. MOLECULAR ENDOCRINOLOGY, 1992, 6 (01) : 53 - 60
  • [50] Opposing effects of interleukin-1 and transforming growth factor-beta on the regulation of tissue-type plasminogen activator and plasminogen activator inhibitor type-1 expression by human mesangial cells
    Wilson, HM
    Haites, NE
    Booth, NA
    [J]. EXPERIMENTAL NEPHROLOGY, 1997, 5 (03): : 233 - 238